Merck and Enumeral predicting clinical drug response

Subscribe via: RSS

Big pharma, Partnering, Pharma

Merck and Enumeral predicting clinical drug response

Posted on 22 December 2014

Enumeral Biomedical has signed an oncology-focused collaborative study agreement with Merck.

The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck.

Searching for more deal information? Current Partnering offers the following options:

CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved.

Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies.

For further deal information visit Current Agreements (subscription required)

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends